colorectal cancer
Conditions
Interventions
FOLFOXIRI plus Cetuximab:FOLFOXIRI plus Cetuximab
FOLFOXIRI plus Bevacizumab:FOLFOXIRI plus Bevacizumab
Sponsors
Fudan University Zhongshan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years old, = 3 months; 10. Good hematological function: neutrophil >= 1.5 x 10^9/l and platelet count >= 100x10^9 / L; HB >= 9g / dl (within one week before randomization); 11. Normal liver and kidney function: serum bilirubin <= 1.5x normal upper limit (ULN), alkaline phosphatase <= 5x ULN, serum transaminase (AST or ALT) <= 5x ULN (within one week before randomization); 12. Sign the written informed consent to participate in the experiment.
Exclusion criteria
Exclusion criteria: 1. Patients with liver metastases from colorectal cancer who have previously received targeted therapy, chemotherapy, radiotherapy or interventional therapy; 2. Known or suspected extrahepatic metastasis; 3. Patients with known hypersensitivity to any component of the study treatment; 4. Clinical related coronary heart disease or history of myocardial infarction in the last 12 months or left ventricular ejection fraction lower than normal range; 5. Acute or subacute intestinal obstruction; 6. Pregnancy (no pregnancy confirmed by serum / urine ß- hCG) or breastfeeding; 7. Other malignant tumors occurred within 5 years, except those with skin basal cell carcinoma or cervical invasive carcinoma; 8. Known drug / alcohol abuse; 9. No legal capacity or limited legal capacity; 10. There are peripheral neuropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| conversion-to-resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;progress-free survival;overall survival;Incidence of adverse events; | — |
Countries
China
Contacts
Public ContactJianmin Xu
Fudan University Zhongshan Hospital
Outcome results
None listed